Related Experiment Video
Updated: Jan 31, 2026

07:46
Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
26.0K
Interglial Crosstalk in Obesity-Induced Hypothalamic Inflammation
Md Habibur Rahman1, Min-Seon Kim2, In-Kyu Lee3
1Department of Pharmacology, Brain Science and Engineering Institute, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, South Korea.
Frontiers in Neuroscience
|January 9, 2019
Summary
Glial cell communication in the brain
Area of Science:
- Neuroscience
- Metabolic Disorders
- Cellular Signaling
Background:
- Glial cells are increasingly recognized for their roles in neuroinflammation and metabolic diseases like obesity and diabetes.
- Crosstalk between glial cells in the central nervous system (CNS) influences brain physiology and pathology.
- Hypothalamic inflammation, driven by malfunctioning glia, is linked to metabolic dysfunction.
Purpose of the Study:
- To review recent advances in the molecular mechanisms of interglial crosstalk in hypothalamic inflammation.
- To highlight the role of glial crosstalk in obesity, diabetes, and associated complications.
- To discuss therapeutic strategies targeting glial cells and their communication pathways.
Main Methods:
- Literature review focusing on molecular aspects of glial cell interactions.
- Analysis of recent studies on hypothalamic inflammation and metabolic disorders.
- Synthesis of evidence linking glia-glia crosstalk to overnutrition-induced inflammation.
Main Results:
- Malfunctioning glia and their signaling are key contributors to hypothalamic inflammation.
- Glia-glia crosstalk is a critical mechanism in chronic hypothalamic inflammation induced by overnutrition.
- This crosstalk is intrinsically linked to the development and progression of obesity and diabetes.
Conclusions:
- Interglial crosstalk plays a central role in hypothalamic inflammation, obesity, and diabetes.
- Targeting glial cells and their communication offers potential therapeutic avenues for metabolic dysfunctions.
- Further research is needed to overcome challenges in developing these therapeutic strategies.
More Related Videos
Related Concept Videos
Hypothalamic-Pituitary Axis
66.0K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
66.0K
Inflammation
62.0K
Overview
62.0K
Obesity
1.3K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Drug Dosing: Obese Patients
263
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
282
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
282
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
181
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
181

